ThursdayFeb 22, 2024 1:00 pm

Florida Moves Closer to Outlawing Delta-8 Products from Hemp

Florida may soon ban delta-8 products such as vapes, edible gummies and joints. This comes after senators approved a measure that would prevent naturally occurring or synthetic delta-8 and delta-10 from being sold legally as hemp products. Delta-8 and delta-10 can produce a psychoactive high when consumed. Delta-8 is a naturally occurring tetrahydrocannabinol (“THC”) compound; THC is one of the two main psychoactive compounds found in the marijuana plant, the other being cannabidiol (“CBD”). An identical measure in Florida’s house, HB 1613, may soon be voted on. The senate measure in question, SB 1698, would impose a limit on the…

Continue Reading

TuesdayFeb 20, 2024 3:30 pm

Advocates Happy the USDA Included Hemp in its Census

Enhancing federal oversight of hemp and addressing key concerns within the marijuana industry will now be more feasible after hemp receives dedicated recognition in the US Department of Agriculture’s (“USDA”) Census of Agriculture, according to industry stakeholders. Joshua Bates, a statistician at USDA, highlighted the significance of hemp being included in the 2022 Ag Census, which was released recently. He emphasized the extensive scope of the census, which offers county-level information on hemp production, a feature not included in the yearly National Hemp Report. The census provides a thorough overview of many farming-related topics, allowing for in-depth examination and additional…

Continue Reading

TuesdayFeb 20, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a…

Continue Reading

ThursdayFeb 15, 2024 11:25 am

New Report Shows the Market for Hemp is Set for Explosive Growth

A recent study has found that by 2027, the value of the global market size of industrial hemp will have hit $18.6 billion. This valuation will be reached if the market grows at the projected compound annual growth rate of 22.4%. The global hemp market is based on source, type, region and application. Based on source, it is classified into organic or conventional, and when it comes to application, this market is studied across textiles, food and beverages, pharmaceuticals and personal-care products. On the basis of type, the market is categorized into hemp fiber, hemp oil and hemp seed, among…

Continue Reading

WednesdayFeb 14, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”)…

Continue Reading

TuesdayFeb 13, 2024 12:30 pm

Normann Copenhagen Unveils Chairs Manufactured from Eelgrass, Hemp

Stockholm Design Week 2024 has seen companies launch various products, among them Foersom & Hiort-Lorenzen, which launched a new collection of plant-base furniture in collaboration with Normann Copenhagen. The collection comprises of a pair of chairs, one of which combines hemp with eelgrass and another made purely from hemp. Eelgrass is a plant similar to seaweed. To create shells, the design duo preferred to use the aforementioned biomaterials instead of injection-molded plastic. They used hemp stems sourced from farms that discarded the stems as a waste product. For their eelgrass chair, they combined dried eelgrass that washed up on the…

Continue Reading

MondayFeb 12, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the previous year, ultimately asserting market dominance and making 2024 its best year yet Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its ambitious plans for the 2024 calendar year. In his annual letter, Chris Bunka, Lexaria’s CEO, noted that this would mark the year that will…

Continue Reading

ThursdayFeb 08, 2024 1:30 pm

Florida House Committee Approves Bill Banning Several Hemp-Derived Products

Legislators in Florida have approved HB 1613, which would regulate hemp products. The measure’s approval by the state’s legislature will prevent patients with various conditions, among them idiopathic genetic epilepsy, from using these products to manage their symptoms. The measure’s version in the Senate, SB 1698, would also prohibit the use of delta-8 THC, a psychoactive compound found in the marijuana plant. While the U.S. Food and Drug Administration (“FDA”) believes that this cannabinoid has intoxicating and psychoactive effects, some individuals have revealed that it provides medicinal benefits. Data from the National Cannabis Industry Association shows that currently, delta-8 is…

Continue Reading

MondayFeb 05, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Positioning TRACER 1000(TM) as Next-Generation Solution for the Explosive Trace Detector Market

1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”) in markets that accept ECAC certification The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders Astrotech is working to position its product as the next-generation solution for the ETD market at a time when many of the existing IMS-based ETDs are due for replacement Keenly watching the developments in the field of explosives and narcotics detection at airports is Astrotech (NASDAQ: ASTC), a mass spectrometry company…

Continue Reading

ThursdayFeb 01, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June These studies will evaluate DehydraTECH for the improved…

Continue Reading

HempWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722